| Pair Name | Shikonin, Temozolomide | ||
| Phytochemical Name | Shikonin (PubChem CID: 479503 ) | ||
| Anticancer drug Name | Temozolomide (PubChem CID: 5394 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Shikonin, Temozolomide | |||
| Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
| Biological Phenomena | Inhibition-->Epithelial-mesenchymal transition | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | MMP2 | hsa4313 | |
| Down-regulation | Expression | MMP9 | hsa4318 | |
| Down-regulation | Expression | SNAI2 | hsa6591 | |
| Down-regulation | Expression | VIM | hsa7431 | |
| In Vitro Model | U-118MG | Astrocytoma | Homo sapiens (Human) | CVCL_0633 |
| Result | From our results we conclude that dual treatment with SHK and TMZ may constitute a powerful new tool for GBM treatment by reducing therapy resistance and tumor recurrence. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell Oncol (Dordr). 2017 Jun;40(3):247-261. doi: 10.1007/s13402-017-0320-1. | Click |
